Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Juneteenth
Heatwaves
Artificial Intelligence
Social Media
World Cup
War
Amazon
Education
Donald Trump
Law
European Union
Cryptocurrency
Published • loading... • Updated

Pitolisant Shows Benefit for IH in Phase 3 Open-Label Trial, with Bruce Corser, MD

Summary by hcplive.com
At SLEEP 2025, Bruce Corser, MD, discussed promising open-label data on pitolisant’s impact on idiopathic hypersomnia symptoms with HCPLive.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
hcplive.comhcplive.com

Pitolisant Shows Benefit for IH in Phase 3 Open-Label Trial, with Bruce Corser, MD

At SLEEP 2025, Bruce Corser, MD, discussed promising open-label data on pitolisant’s impact on idiopathic hypersomnia symptoms with HCPLive.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

hcplive.com broke the news in on Wednesday, June 18, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Maryland icon

Maryland

News
For You
SearchBlindspotLocal